With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs

Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players. The post With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and…

Read More

Digital Biomarkers in Agitation Detection: Enhancing Care for Communication-Impaired Neurological Disorders

Wearable technology seems to offer great potential for early detection and management of agitation experienced by people with communication-impaired neurological disorders, allowing caregivers to provide personalized interventions that could significantly improve patients’ lives. The post Digital Biomarkers in Agitation Detection: Enhancing Care for Communication-Impaired Neurological Disorders appeared first on MedCity News.

Read More

Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But It Nullifies Hefty Fine

The European Union’s highest court sided with Illumina, agreeing that the European Commission had no authority to review the acquisition of liquid biopsy company Grail. The ruling comes after Illumina stopped challenging antitrust litigation, opting to instead spin out Grail as a standalone company. The post Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But…

Read More

Health Literacy Is Not a Multi-Language Insert

We must empower health plan  members with culturally and linguistically-relevant information about their benefits and health – tools that in turn encourage them to adopt a proactive and informed approach to their well-being. The post Health Literacy Is Not a Multi-Language Insert appeared first on MedCity News.

Read More